COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Assess the Effect of Daily Treatment of Vardenafil 20mg or Sildenafil 100mg and Placebo on Sperm Function

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00655590
Recruitment Status : Completed
First Posted : April 10, 2008
Last Update Posted : December 30, 2014
Information provided by (Responsible Party):

Brief Summary:
Assess the effect of daily treatment of vardenafil 20mg or sildenafil 100mg and placebo on sperm function

Condition or disease Intervention/treatment Phase
Erectile Dysfunction Drug: Levitra (Vardenafil, BAY38-9456) Drug: Sildenafil Drug: Placebo Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 200 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Placebo Controlled, Parallel Arm, Multicenter Trial Assessing the Effect of Daily Treatment of Vardenafil 20 mg or Sildenafil 100 mg Compared to Placebo on Spermatogenesis
Study Start Date : January 2005
Actual Primary Completion Date : June 2006
Actual Study Completion Date : June 2006

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Arm 1 Drug: Levitra (Vardenafil, BAY38-9456)
20 mg daily dosing

Active Comparator: Arm 2 Drug: Sildenafil
100 mg daily dosing

Placebo Comparator: Arm 3 Drug: Placebo
Matching placebos

Primary Outcome Measures :
  1. Proportion of vardenafil subjects with a 50% or greater decrease from baseline in mean sperm concentration at 6 months (LOCF), compared to placebo after repeated use [ Time Frame: 24 weeks ]

Secondary Outcome Measures :
  1. Mean sperm concentration [ Time Frame: 24 weeks ]
  2. Mean sperm count [ Time Frame: 24 weeks ]
  3. Sperm morphology [ Time Frame: 24 weeks ]
  4. Sperm motility [ Time Frame: 24 weeks ]
  5. Reproductive hormones [ Time Frame: 24 weeks ]
  6. Proportion of sildenafil subjects with a 50% or greater decrease from baseline in mean sperm concentration at 6 months (LOCF), compared to placebo and vardenafil after repeated use [ Time Frame: 24 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   25 Years to 64 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy male subjects or men with ED aged 25 - 64
  • Baseline sperm conc. of > 20 mio / ml- Normal World Health Organization A+B+C sperm mortality > 50%- Normal sperm morphology (WHO, 1992 manual criteria) > 30% and - 1.0 mL ejaculate volume at each of the 3 analyses during the screening phase.

Exclusion Criteria:

  • Presence of any psychological or physiological abnormalities that in the opinion of the Investigator would significantly impair sexual performance or ability to provide semen samples according to the protocol- Spinal cord injury
  • History of surgical prostatectomy
  • Other exclusion criteria apply according to US Product Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00655590

Layout table for location information
United States, Arizona
Phoenix, Arizona, United States, 85023
Tempe, Arizona, United States, 85282
United States, California
Beverly Hills, California, United States, 90212
La Mesa, California, United States, 91942-3058
Laguna Hills, California, United States, 92653
San Diego, California, United States, 92128
Torrance, California, United States, 90502-2004
Van Nuys, California, United States, 91405
United States, Connecticut
Waterbury, Connecticut, United States, 06708
United States, Florida
Aventura, Florida, United States, 33180
United States, Louisiana
New Orleans, Louisiana, United States, 70112
United States, Michigan
Ann Arbor, Michigan, United States, 48109-0330
United States, Minnesota
Minneapolis, Minnesota, United States, 55455
Rochester, Minnesota, United States, 55905
United States, New York
Great Neck, New York, United States, 11021
New York, New York, United States, 10016-4576
United States, Ohio
Cincinnati, Ohio, United States, 45212-2787
United States, Texas
San Antonio, Texas, United States, 78229
Sponsors and Collaborators
Layout table for investigator information
Study Director: Bayer Study Director Bayer
Layout table for additonal information
Responsible Party: Bayer Identifier: NCT00655590    
Other Study ID Numbers: 11520
First Posted: April 10, 2008    Key Record Dates
Last Update Posted: December 30, 2014
Last Verified: December 2014
Keywords provided by Bayer:
Erectile Dysfunction
Sperm concentration
Sperm count
Reproductive hormonal
Additional relevant MeSH terms:
Layout table for MeSH terms
Erectile Dysfunction
Sexual Dysfunction, Physiological
Genital Diseases, Male
Sexual Dysfunctions, Psychological
Mental Disorders
Sildenafil Citrate
Vardenafil Dihydrochloride
Vasodilator Agents
Phosphodiesterase 5 Inhibitors
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Urological Agents